Naturally presented HLA class I–restricted epitopes from the neurotrophic factor S100-β are targets of the autoimmune response in type 1 diabetes

Cristina Calviño-Sampedro,*,1 Iria Gomez-Tourino,*,1,2 Oscar J. Cordero,*, Pedro A. Reche,‡ Marta Gómez-Perosanz,† Jose Luis Sánchez-Trincado,† Miguel Ángel Rodríguez,‡ Aurelio M. Sueiro,§ Juan E. Viñuela,§ and Rubén Varela Calviño*,3

*Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, and †Departamento de Biología Funcional, Centro de Investigación en Biología (CIBUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; ‡Departamento de Inmunología, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain; and §Servicio de Endocrinología y Nutrición, Hospital de Conxo, and ‡Servicio de Inmunología, Hospital Clínico Universitario, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago de Compostela, Spain

ABSTRACT: Type 1 diabetes (T1D) results from the destruction of pancreatic β-cells by the immune system, and CD8+ T lymphocytes are critical actors in this autoimmune response. Pancreatic islets are surrounded by a mesh of nervous cells, the peri-insular Schwann cells, which are also targeted by autoreactive T lymphocytes and express specific antigens, such as the neurotrophic factor S100-β. Previous work has shown increased proliferative responses to whole S100-β in both human T1D patients and the nonobese diabetic (NOD) mouse model. We describe for the first time naturally processed and presented epitopes (NPPEs) presented by class I human leukocyte antigen–A*02:01 (A2.1) molecules derived from S100-β. These NPPEs triggered IFN-γ responses more frequently in both newly diagnosed and long-term T1D patients compared with healthy donors. Furthermore, the same NPPEs are recognized during the autoimmune response leading to diabetes in A2.1-transgenic NOD mice as early as 4 wk of age. Interestingly, when these NPPEs are used to prevent diabetes in this animal model, an acceleration of the disease is observed together with an exacerbation in insulin and an increase in S100-β–specific cytotoxicity in vaccinated animals. Whether these can be used in diabetes prevention needs to be carefully evaluated in animal models before use in future clinical assays.—Calviño-Sampedro, C., Gomez-Tourino, I., Cordero, O. J., Reche, P. A., Gómez-Perosanz, M., Sánchez-Trincado, J. L., Rodríguez, M. Á., Sueiro, A. M., Viñuela, J. E., Calviño, R. V. Naturally presented HLA class I–restricted epitopes from the neurotrophic factor S100-β are targets of the autoimmune response in type 1 diabetes. FASEB J. 33, 6390–6401 (2019). www.fasebj.org

KEY WORDS: cytotoxic lymphocytes · autoantigen · S100β peptide epitopes · immunotherapy · peri-insular Schwann cells

One of the hallmarks of type 1 diabetes (T1D) in both human patients and nonobese diabetic (NOD) mice is the destruction of the insulin-producing β-cells in the pancreatic islets. The autoimmune origin of this attack comes from several lines of evidence, including the detection of autoantibodies years before clinical disease onset (1) and the detection of T lymphocytes specific for the very same antigens (2–5). During this process, pancreatic islets are infiltrated by different immune cell types, including CD4+ and CD8+ T lymphocytes (4, 6, 7). However, CD8+ lymphocytes are critical for diabetes development. First, neither insulitis

ABBREVIATIONS: A2.1, A*02:01; BB7.2, anti-human HLA-A*02:01–FITC mAb; CTL, cytotoxic T lymphocyte; ELISPOT, enzyme-linked immunospot; GAD65, glutamic acid decarboxylase 65; GFAP, glial fibrillary acidic protein; HD, healthy donor; HLA, human leukocyte antigen; HLA-DR4, HLA-DRB1*04:01; IA-2, insulinoma-associated protein 2; IFA, incomplete Freund’s adjuvant; K562/A2.1, HLA-A*02:01–expressing K562 cell line; LS, long standing; MHC, major histocompatibility complex; MS, mass spectrometry; ND, newly diagnosed; NOD, nonobese diabetic; NPPE, naturally processed and presented epitope; PBMC, peripheral blood mononuclear cell; pSC, peri-insular Schwann; ROC, receiver-operating characteristic; SI, stimulation index; TBS, Tris-buffered saline

1 These authors contributed equally to this work.
2 Current affiliation: BioFarma Research Group, Department of Pharmacology, Pharmacy and Pharmaceutical Technology. CIMUS Research Center. University of Santiago de Compostela, Santiago de Compostela, Spain.
3 Correspondence: Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Campus Vida s/n, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, La Coruña, Spain. E-mail: ruben.varela@usc.es

This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
doi: 10.1096/fj.201802270R
This article includes supplemental data. Please visit http://www.fasebj.org to obtain this information.
nor diabetes develops in NOD mice lacking major histocompatibility complex (MHC) class I molecules and CD8+ T cells (8). Second, in human TID, there is a linkage to susceptibility to particular human leukocyte antigen (HLA) class I molecules, such as A*2401 and A*0201, and also to protection, such as A*01 and A*1101 (9, 10). Finally, in human TID patients, CD8+ T lymphocytes are the predominant cell subset seen in insulitic lesions linked to a hyperexpression of HLA class I molecules (2, 11, 12).

Several targets of this inflammatory response have been identified, among which preproinsulin, glutamic acid decarboxylase 65 (GAD65), and insulinoma-associated protein 2 (IA-2)–β have been repeatedly cited in the literature (13). Recent results in both the NOD mice and human TID patients have led to the identification of other important targets for those autoreactive T lymphocytes, such as glial fibrillary acidic protein (GFAP) and the neurotherophic factor S100-β. Those antigens have been shown to be targeted by autoantibodies (19, 20) and T lymphocyte responses (16, 21–25). Lymphocyte proliferation against GFAP and S100-β antigens has been demonstrated in NOD mice and human TID patients (16, 22). In the case of GFAP, I-Aβ7 and Kα peptide epitopes have been described in NOD mice (21), and HLA-A2.1–restricted peptide epitopes have been described in humans (24). Recently, naturally processed and presented epitopes (NPPEs) derived from S100-β, restricted by the HLA-DRB1*04:01 (HLA-DR4) class II molecule, and targeted by the autoimmune response in TID patients have been identified (23). In NOD mice, peptide epitopes derived from S100-β and recognized by CD8+ T lymphocytes have also been described (25); interestingly, dominant S100-β–derived epitopes in NOD mice lie within the same regions as those targeted by human T responses.

Immunotherapies employing either whole GFAP or S100-β protect NOD mice from diabetes development (16). Moreover, immunotherapy with class II I-Aβ7– and class I Kα–restricted peptide epitopes derived from GFAP protect NOD mice from diabetes development (21). These data indicate that immunotherapy with pSC-derived antigens could prevent the development of clinical symptoms.

Despite these results, no S100-β peptide epitopes targeted by CD8+ cytotoxic T lymphocytes (CTLs) in TID patients have been identified, nor has their potential effectiveness in preventing diabetes development been reported. In the present study, we have identified several NPPEs derived from S100-β and presented by the class I HLA molecule A*02:01 (A2.1). We hypothesized that responses against these peptide epitopes might be present in both human TID patients and A2.1–transgenic NOD mice. Our results support this hypothesis: higher responses against some S100-β–derived NPPEs can be detected more frequently in both newly diagnosed (ND) and long-term TID patients. Furthermore, TID patients respond more frequently and with higher intensity to more than 1 epitope. Similar responses can be detected in A2.1–transgenic NOD mice as early as 4–5 wk of age. When these peptide epitopes were used for immunotherapy, an apparent acceleration of disease development was observed together with a worsening in the insulitic lesions and increased cytotoxicity against S100-β–positive targets by CTLs. Our results highlight the need for careful evaluation of different administration routes and dosage protocols using this antigen to ameliorate the autoimmune response in TID.

MATERIALS AND METHODS

Cloning of S100-β and generation of an S100-β–expressing surrogate antigen-presenting cell

S100-β cDNA (GenBank accession no. BC001766.1) was obtained from SourceBioscience (Nottingham, United Kingdom) and subcloned into the BamHI site of the pcDNA3.1/Zeo (+) vector (Thermo Fisher Scientific, Waltham, MA, USA).

A surrogate antigen–presenting cell was generated by transfection of an HLA-A2.1–expressing K562 cell line (K562/A2.1) with S100-β–pcDNA3.1-Zeo using Lipofectamine (Thermo Fisher Scientific) following the manufacturer’s instructions. Clones expressing high levels of S100-β were selected using Geneticin and Zeocin (Thermo Fisher Scientific).

Expression of both A2.1 and S100-β epitopes was verified by flow cytometry and immunofluorescence. For flow cytometry, cells were surface stained with an anti-human HLA-A2.1–FITC mAb (BB7.2 clone) (BD Biosciences, San Jose, CA). After washing, cells were fixed and permeabilized (Cytofix/Cytoperm; BD Biosciences) and stained intracellularly with a mouse anti–S100-β mAb (Abcam, Cambridge, MA, USA) followed by an anti-mouse IgG phycoerythrin-labeled goat mAb (Abcam) and analyzed using a BD FACS caliber flow cytometer (BD Biosciences).

For immunofluorescence analysis, cells were fixed onto poly-l-Lysine–coated coverslips; stained with either the BB7.2–FITC antibody (surface) or, after fixation/permeabilization, the S100-β–FITC antibody (Abcam) (intracellular) and DAPI; and imaged in an Olympus BX51 fluorescence microscope (Olympus, Tokyo, Japan).

Identification of HLA-A2.1–restricted NPPEs derived from S100-β

Peptides bound to A2 in the cell surface of either K562/A2.1 or K562/A2.1–S100-β were eluted by a brief incubation in acid citrate buffer (pH 3.3) and sequentially enriched using a 3 kDa cutoff Amicon Ultra Filter (MilliporeSigma, Burlington, MA, USA) and a Discovery DSC-18 trifunctional C18 silica resin column (MilliporeSigma). Peptide fractionation was done using a 150 mm × 2.1 mm BioBasic 18 column (Thermo Fisher Scientific), and peptide-containing fractions were stored at −80°C until analysis by mass spectrometry (MS).

MS was carried out in the Spectrometry Service [Instituto de Investigaciones Sanitarias (IDIS), Santiago de Compostela] on a matrix-assisted laser desorption/ionisation–time-of-flight mass spectrometer (MALDI-TOF) MS Analyzer (Thermo Fisher Scientific). The analysis was carried out with the 4000 Series Explorer software v.3.5 (Thermo Fisher Scientific) and Mascot v.2.1 (Matrix Science, Boston, MA, USA) to search against a National Center for Biotechnology Information nonredundant (NCBI nr) protein database or in an S100-β–specific database. Unique m/z values were identified using Findpep (http://web.expasy.org/findpep/) to select those that could be derived from S100-β. Potential unique peptide epitopes of 8–10 aa long were chosen.

NOVEL S100-β EPITOPES IN TYPE 1 DIABETES

6391
**In vitro proteasome digestion and in silico proteasomal cleavage analysis of purified human S100-β**

Purified human S100-β (23) was incubated with purified 20S proteasome (Enzo Life Sciences, Farmingdale, NY, USA) (molar ratio 250:1) in digestion buffer [30 mM Tris-HCl (pH 8.0), 10 mM NaCl, 2 mM MgCl₂, 1 mM DTT, 0.01% sodium dodecyl sulfate] for 16 h at 37°C. As a control, the same digestion was set up with either no proteasome or with acetic acid (1%)-inactivated proteasome. Generated peptides were purified and concentrated using a cationic resin (ZipTip with strong cation exchange; MilliporeSigma) following the manufacturer’s instructions. Retained peptides were eluted from the resin and analyzed by MS.

The S100-β human protein sequence was analyzed in silico for potential proteasome and immunoproteasome cleavage sites using several published algorithms (26, 27).

**Peptides**

S100-β–derived NPPEs S10010–18 (ALIDVFHQY) and S10020–28 (GREGDKHKL) were synthesized by ChinaPeptide (Hangzhou, China) to ∼90% purity. A stock of 100 mg/ml in DMSO was prepared for each peptide and stored at −20°C until use.

**HLA stabilization assay**

Binding of the S100-β NPPE candidates was examined by a conventional HLA stabilization assay as previously described (28). Briefly, T2 cells were washed twice with serum-free AIM V medium (Thermo Fisher Scientific) and incubated in medium containing β2-microglobulin (MilliporeSigma) and each of the test peptides at various concentrations (100–0.78 μM). Surface A2.1 expression was determined using the BB7.2 antibody in a FACSCalibur flow cytometer.

**Human donors**

In total, 35 subjects were studied: 18 nondiabetic healthy donors (HDs) without family history of disease and 7 ND (<1 yr) T1D patients. Blood was drawn with the informed consent of all subjects and appropriate permission was obtained from the Institutional Ethics Committee (Comité Ético de Investigación Clínica de Galicia, CEIC). T1D patients were enrolled from those attending the diabetic clinic at the Endocrinology Service (Hospital de Conxo, Santiago de Compostela, Spain). Healthy nondiabetic donors were recruited from laboratory and hospital staff during the same period. HLA-DR4 and HLA-A2.1 positivity was determined by PCR as previously described by Bunce (29). GADA and IA-2 autoantibodies were determined by ELISA (Palex Medical, Barcelona, Spain).

**Mice**

Transgenic NOD.B6-Tg(HLA-A2.1)1Enge/DvsJ mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and maintained in the specific-pathogen–free facilities at the Molecular Medicine and Chronic Diseases Research Centre (Santiago de Compostela). Glucosuria was determined weekly from 8 wk of age onward using Medi-Test Glucose Strips (Macherey-Nagel, Düren, Germany). Diabetes was diagnosed when glucose levels were ≥500 mg/dl (27.8 mM) in 2 consecutive measures. All experimental procedures were approved by the corresponding ethics committee. Splenocytes were stained with the BB7.2 antibody to confirm A2.1 expression.

To obtain single-cell suspensions, spleens were passed through a 70-μm pore size filter (Corning cell strainer; Corning, Corning, NY, USA) and centrifuged over a Ficoll gradient.

**S100-β NPPE immunotherapy**

An immunotherapy protocol was performed as previously described by Han et al. (30). Briefly, female mice were immunized intraperitoneally with a 1:1 mixture of S10010–18 and S10020–28 in saline. Immunizations started at 4 wk of age and were performed every 2 wk until 8 wk of age or 3 wk thereafter. Mice were followed until they became diabetic or reached 30 wk of age. High (100 μg/peptide) and low (10 μg/peptide) peptide doses were evaluated. As a control, female mice were inoculated with saline containing DMSO (0.2%).

**Insulitis and immunohistochemistry**

Bouin-fixed pancreases were included in paraffin, and 3 parallel series with 16 μm thick sections were obtained. Sections were stained with hematoxylin-eosin, and between 30 and 50 islets per mouse were scored in a blinded fashion. Quantification of insulitis with age was done using 5–6 animals per age group. Insulitis score in treated animals was determined after diabetes diagnosis or at 30 wk of age. Each islet was scored according to the scale indicated in the supplemental data.

For immunohistochemistry, pancreases were fixed in 4% paraformaldehyde. Sections were pretreated with Proteinase K (10 mg/ml) for 5 min at room temperature. Sections were rinsed in 0.05 M Tris-buffered saline (TBS) (pH 7.4) for 5 min and treated with 10% H₂O₂ in TBS (30 min, room temperature). After rinsing in 0.05 M TBS (pH 7.4) for 5 min, sections were incubated overnight at room temperature with an anti-GFAP mouse mAb (clone 2A5; Abcam). Sections were rinsed 3 times in TBS (10 min each) and incubated with an anti-mouse horseradish peroxidase–coupled secondary antibody (1 h, room temperature). Sections were developed with 0.25 mg/ml diaminobenzidine tetrahydrochloride (MilliporeSigma) in TBS (pH 7.4) and 0.00075% H₂O₂ and counterstained with hematoxylin-eosin. All dilutions were made with TBS containing 15% normal goat serum (MilliporeSigma) and 0.2% Triton X-100 (MilliporeSigma). All incubations were carried out in a humid chamber. Finally, the sections were dehydrated and mounted.

**Enzyme-linked immunospot assays**

IFN-γ enzyme-linked immunospot (ELISPOT) assays (U-CyTech Biosciences, Utrecht, The Netherlands) were used to detect S100-β–specific responses according to the manufacturer’s instructions. Mouse splenocytes were used in all assays, and an indirect ELISPOT assay was performed with a 6-h prestimulation step. When human responses were analyzed, a direct ELISPOT assay was performed (3 × 10⁴ peripheral blood mononuclear cells (PBMCs)/well in triplicates per antigen) with a 24-h stimulation period with the corresponding peptide/antigen.

Peptides were added to a final concentration of 10 μM. Both culture medium alone and DMSO (0.5%) were used as negative controls. CEF Peptide Pool (Mabtech AB, Nacka, Sweden) or concanavalin A (25 ng/ml) were used as positive controls in human and mouse ELISPOTs, respectively.

Data are expressed as a stimulation index (SI) (SI = total spots with antigen/total spots with DMSO). In human ELISPOTs, a response was considered positive when the SI was above the threshold determined using receiver-operating characteristic (ROC) curves. In mouse ELISPOTs, a response was considered positive when the SI was >2.

**Cytotoxicity assays**

Lysis of peptide-loaded targets was done as previously indicated by Neri et al. (31). Briefly, splenocytes from young nondiabetic female mice were used as targets, whereas splenocytes from either saline- (n = 5) or S100-β– (n = 13) vaccinated mice were used.
as effectors. Target cells were incubated 2 h with S100-β NPPEs (both at 10 nM) or DMSO and stained with calcein (15 mM) (MilliporeSigma). Cells were washed, and 1 × 10^6 cells were plated in U-bottom, 96-well plates. Effector cells were added in quadruplicates at different effector:target ratios (1:1 to 40:1). Maximum lysis was obtained by adding 2% Triton X-100 to target cells, and spontaneous lysis was obtained by adding culture medium to target cells. After 4 h of incubation, fluorescence was determined in a Synergy H1M plate reader (BioTek Instruments, Winooski, VT, USA). The percentage of cytotoxicity was calculated as (MF_{sample} − MF_{spontaneous})/(MF_{maximum} − MF_{spontaneous}) × 100, where MF is mean fluorescence.

Statistical analysis

Differences in the percentage of highly infiltrated islets and the frequency of positive responses among different groups were analyzed using Fisher’s exact test. Comparisons. Survival was analyzed using the log-rank Mantel-Cox test. A value of p < 0.05 was considered significant. All statistical analysis was done using SPSS v.24 (IBM SPSS, Chicago, IL, USA) and Prism (GraphPad, La Jolla, CA, USA).

RESULTS

Generation of surrogate antigen-presenting cells for the identification of A2.1-restricted S100-β-derived NPPEs

Several clones were obtained from the original K562-A2.1/S100-β cell line, and 4 were selected based on their expression of both A2.1 and S100-β (Supplemental Fig. S1A, B), confirming the generation of a surrogate antigen-presenting cell.

No significant differences were noted between chromatograms from K562/A2.1 and K562/A2.1−S100-β−eluted peptides (Supplemental Fig. S1C). In total, 44 peptide-containing fractions were analyzed by MS, identifying 7298 and 7027 m/z masses from K562/A2.1 and K562/A2.1−S100-β cells, respectively. Up to 3403 m/z could be derived from S100-β, allowing a 1 Da error, with just 2035 m/z remaining when only peptides between 8 and 11 aa long were kept. These m/z masses were compared with the equivalent fraction derived from K562/A2.1 cells as well as the immediately preceding and posterior fractions looking for unique masses. This analysis led to the identification of 4 unique candidate masses (Table 1). Most predictions for each experimental m/z correspond either to overlapping peptides or peptides lying within the same short region of S100-β (Table 1).

Proteasome cleavage and A2.1 binding affinity of candidate S100-β NPPEs

From all the sequences shown in Table 1, potential proteasome cleavage sites are predicted by several algorithms for 5 peptide sequences (10–18 ALIDVFHQY; 20–28 GREGDKHKL; 38–45 NNELSHFL; 54–61 VDKVMETL; 67–75 GECFQEFM). We next determined the in vitro proteasome cleavage pattern of S100-β by digestion with purified 20S proteasome. The use of active proteasome generates multiple unique fragments (Fig. 1A, B, bottom panels), which were not present when S100-β was incubated alone (Fig. 1A, B, top panels) or with inactivated proteasome (Fig. 1A, B, middle panels). Unique m/z present in samples of S100-β incubated with active proteasome were analyzed by tandem MS and Mascot, and 9 of them were identified as being derived from S100-β (Fig. 1, A, B, bottom panels, arrows), with many of these corresponding to its amino-terminal end (Fig. 1C). Comparison of proteasome-generated peptides with A2.1-eluted peptide MS data (Table 1) indicates that the carboxy-terminal end of peptides S100_{10–18} (ALIDVFHQY) and S100_{20–28}

| Experimental m/z | Theoretical m/z | ΔDa | Sequence | Position |
|------------------|-----------------|-----|----------|----------|
| 935.26           | 954.491         | −0.934 | VDKVMETL | 54–61    |
| 935.359          | 954.359         | −0.091 | ETLDNSGDKG | 59–67   |
| 935.359          | 954.359         | −0.067 | TLDNDDGDGE | 60–68  |
| 935.359          | 954.359         | 0.971  | VMETLNDND | 57–64   |
| 974.290          | 973.474         | −0.164 | INNELSHFL | 38–45   |
| 974.290          | 973.474         | −0.164 | NNELSHFL | 38–45   |
| 974.290          | 973.474         | −0.816 | EIKEQEFV | 47–54   |
| 974.290          | 973.474         | −0.769 | LKKSELK  | 27–34   |
| 974.290          | 973.474         | 0.065  | GECFQEF | 67–74   |
| 974.290          | 973.474         | 0.225  | KEQWDK | 49–56   |
| 974.290          | 973.474         | 0.298  | NKKSELKE | 28–35  |
| 974.290          | 973.474         | 0.298  | KKKSELK | 29–36   |
| 1039.565         | 1039.480        | −0.084 | VQSGREGDK | 17–25  |
| 1039.565         | 1039.564        | 0.000  | GREGDKHKL | 20–28   |
| 1105.506         | 1105.396        | −0.109 | GECFQEF | 67–75   |
| 1105.506         | 1105.568        | 0.061  | ALIDVFHQY | 10–18  |

ΔDa, difference between experimental and theoretical m/z (in Da); Experimental m/z, unique m/z present only in the peptide mix derived from K562/A2.1−S100-β cells; Position, amino acid position in the S100-β protein of the predicted peptide; Sequence, amino acid sequence of the predicted peptide; Theoretical m/z, m/z predicted by Findpept.
(GREGDKHKL) is generated by the proteasome, making these sequences potential HLA class I–restricted epitopes. MS data and proteasome cleavage were the 2 main criteria to select the NPPEs to be evaluated in the ELISPOT assays.

Of the 5 peptides with the potential proteasome cleavage sites indicated above, only peptide S100<sub>10–18</sub> (ALIDVFHQY) demonstrated some weak binding affinity for A2.1, whereas for the other 4 S100-β peptides, no binding affinity could be demonstrated (Supplemental Fig. S2A). Interestingly, several algorithms (32–35) indicate that S100<sub>10–18</sub> is one of the peptides with the highest binding affinity for A2.1 from all of the potential 9-mer peptides derived from S100-β (Supplemental Fig. S2B). In fact, when combining predictions for processing by the proteasome, transporter associated with antigen processing binding, and A2.1 binding affinity (36), S100<sub>10–18</sub> is once again the peptide showing the highest combined prediction score, followed by S100<sub>67–75</sub> and S100<sub>20–28</sub> (Supplemental Fig. S2B). All of these data combined suggest that peptide epitopes S100<sub>10–18</sub> (ALIDVFHQY) and S100<sub>20–28</sub> (GREGDKHKL) could constitute potential candidates to be recognized by autoreactive CD8<sup>+</sup> T lymphocytes in T1D patients.

T1D patients show specific T-cell responses against A2.1-restricted S100-β–derived NPPEs

We investigated whether lymphocyte responses against S100<sub>10–18</sub> and S100<sub>20–28</sub> could be detected in T1D patients by IFN-γ ELISPOT (see Table 2 for demographic data). ROC analysis gives an optimal SI cutoff of 1.85 and 1.75 for S100<sub>10–18</sub> and S100<sub>20–28</sub>, respectively (Fig. 2A); therefore, an SI ≥2 was chosen to classify a response as positive.

**Figure 1.** MS analysis of in vitro proteasome digestion of purified S100-β. A, B) Spectra corresponding to m/z range of 917–1564 (A) and 1556–3145 (B) are shown. Data for S100-β incubated with no proteasome (top panels), inactive proteasome (middle panels), or active proteasome (bottom panels) are shown. Unique m/z present only in samples of S100-β incubated with active proteasome were subsequently identified by tandem MS and analyzed by Mascot (arrows). C) Sequences of the 9 most intense fragments generated by in vitro digestion of S100-β with purified 20S proteasome are aligned with the amino acid sequence of the antigen. The m/z for each fragment is shown on the left. The carboxy-terminal amino acid is underlined. The sequences of potential peptide epitopes eluted from A2.1 are shown at the bottom (carboxy-terminal amino acid is underlined only if the fragment has been generated by the proteasome and identified by MS). The carboxy-terminal ends of peptides S100<sub>10–18</sub> (ALIDVFHQY) and S100<sub>20–28</sub> (GREGDKHKL) are generated by the proteasome, making them potential class I–restricted peptide epitopes.
Clear responses against at least 1 of the 2 S100-β peptides could be detected (Fig. 2B), and these responses were significantly more frequent among T1D patients than HDs for both S100-β peptide epitopes [S10010–20: 64.7% T1D (11/17) vs. 11.1% HD (2/18), \( P = 0.0016 \); S10020–28: 70.6% T1D (12/17) vs. 16.7% HD (3/18), \( P = 0.002 \). Two-tailed Fisher's exact test]. Positive responses to S10010–18 could be detected in both HLA-A2.1-positive (\( n = 6 \); Fig. 2C, red squares) and HLA-A2.1-negative (\( n = 5 \); Fig. 2C, black squares) T1D patients. A similar result is seen for S10020–28 in HLA-A2.1-positive (\( n = 7 \); Fig. 2D, red squares) and HLA-A2.1-negative (\( n = 6 \); Fig. 2D, black squares) T1D patients. Considering only HLA-A2.1-positive subjects, responses in A2.1+ T1D patients are still significantly higher compared with HD-A2.1+ subjects for S10020–20 responses in A2.1+ T1D patients are still significantly more frequent among T1D patients than HDs (13.7) vs. 2/10 (20.0%), reaching statistical significance only for LS T1D patients (8/28, 28%) when compared with males (1.5) for S10010–20 (\( P = 0.035 \); Mann-Whitney U test) (Fig. 2F). In the case of S10020–28, frequency of positive responses among ND (6/7; 85.7%) and LS T1D patients (6/10; 60.0%) was again higher compared with that seen in HD (2/10; 20%), reaching statistical significance only for ND T1D patients (\( P = 0.015 \); 2-tailed Fisher's exact test) (Fig. 2F).

Furthermore, the magnitude of the responses (median SIs) against S10010–18 were significantly higher in LS T1D patients (13.7) vs. HD (1.0) (Fig. 2E) (\( P = 0.0024 \); Kruskal-Wallis, Dunn's post hoc test). In the case of S10020–28, median responses in ND (4.1) and LS (3.6) T1D patients were significantly higher compared with HD (0.9) (Fig. 2F) (\( P = 0.01 \) and \( P = 0.001 \), respectively; Kruskal-Wallis, Dunn's post hoc test).

Interestingly, dual positivity (i.e., response to both peptides) is more frequently detected in T1D patients (9/17; 52.9%) compared with HDs (1/18; 5.5%) (\( P = 0.0027 \); 2-tailed Fisher's exact test) (Fig. 2G).

In summary, all these data indicate that proinflammatory lymphocyte responses against the 2 novel S100-β NPPEs are more frequent in T1D patients, both ND and LS.

**Immune responses against S100-β-derived NPPEs in the A2.1-transgenic NOD mice**

We examined whether similar responses against the S10010–18 and S10020–28 peptide epitopes could be detected in the A2.1-transgenic NOD mouse preclinical model (37). Diabetes development kinetics and insulitis in both males and females in our colony are shown in Supplemental Fig. S3.

Positive responses by splenocytes against S10010–18 and S10020–28 can be detected in male [8/22 (36.4%) and 8/22 (36.4%), respectively] (Fig. 3A) and female mice [19/31 (61.3%) and 15/31 (48.4%), respectively] (Fig. 3A). There are no statistical differences in the percentage of responses between male and female mice (\( P = 0.09, P = 0.41 \); 2-tailed Fisher's exact test). However, the magnitude of the responses (median SIs) is significantly higher among females (2.6) when compared with males (1.5) for S10010–18 (\( P = 0.035 \); Mann-Whitney U test) (Fig. 3A).

When these responses were examined according to age in female mice, responses to both S100-β-derived NPPEs can be detected as early as 4–5 wk of age (Fig. 3B, C).

These data confirm that S100-β is a target of the autoimmune response in T1D and that epitopes S10010–18 and S10020–28 are targeted by T lymphocytes.

**Immunotherapy of A2.1-transgenic NOD mice with S100-β-derived peptides**

We next evaluated the capacity of these NPPEs to prevent disease development by periodic immunization of young female mice. No significant reduction in disease development frequency is seen compared with saline-inoculated mice (Fig. 4A) (100% vs. 84.6%); \( P = 1.0 \); 2-tailed Fisher's exact test). In fact, S100-β vaccination seems to slightly accelerate T1D development, although this kinetic does
not reach statistical significance (Fig. 4A) ($P = 0.290$; log-rank, Mantel-Cox). However, vaccination does have an effect on the cellular autoimmune response, as the number of highly infiltrated islets is significantly higher in S100b–vaccinated animals (Fig. 4B) ($P = 0.0054$; Fisher’s exact test). Moreover, numerous GFAP-immunoreactive cells are observed around the islets of young nondiabetic control female mice (Supplemental Fig. S4A–D) compared with diabetic S100b–immunized female mice, in which these cells are scarce and show a faint GFAP immunoreactivity (Supplemental Fig. S4E–H, see arrows in panels F and H). Some immunoreactive intra-islet cells are also seen in the pancreatic islets of control animals (Supplemental Fig. S4, arrowheads in panels B and D), which are absent in the immunized animals. These results show a decrease in the number of pSC cells in the S100b–immunized animals compared with young nondiabetic insulitis-free female mice.

Despite this increase in islet infiltration severity, positive responses against S10010–18 (70%, 7/10) (Fig. 4C, S100b) or S10020–28 (50%, 5/10) (Fig. 4D, S100b) are not significantly higher than that observed in nonmanipulated animals (S10010–18: 53.1%, 17/32; S10020–28: 48.4%, 15/31) (Fig. 4C, D, spontaneous) or inoculated with saline (S10010–18: 66.7%, 8/12; S10020–28: 66.7%, 8/12) (Fig. 4C, D, saline) ($P > 0.05$; Fisher’s exact test). Moreover, vaccination with S100b–derived NPPEs does not significantly modify the intensity of the response measured as the median SI ($P = 0.4$; Kruskal-Wallis test).

To address whether the unexpected finding of high islet infiltration in S100b–treated animals was due to the...
increased the number of highly infiltrated islets (Fig. 5B) ($P = 0.011$; Fisher’s exact test).

Similar to the results seen using high doses, IFN-γ responses in mice vaccinated with S10010–18 and S10020–28 [6/13 (46.1%) and 7/13 (53.8%), respectively] are not significantly higher compared with those seen in animals inoculated with saline [S10010–18: 66.7% (8/12); S10020–28: 66.7% (8/12)] or those developing T1D spontaneously [S10010–18: 61.3% (19/31); S10020–28: 48.4% (15/31)] (Fig. 5C, D) ($P > 0.05$; Fisher’s exact test). Moreover, vaccination with S100-β–derived NPPEs does not significantly modify the intensity of the response ($P = 0.24$ for S10010–18 and $P = 0.097$ for S10020–28; Kruskal-Wallis test). However, the immunotherapy regime seems to activate the cellular autoimmune response against S100-β because a significant increase in the cytotoxic activity against splenocytes incubated with the peptide epitopes is seen (Fig. 5E) ($P < 0.05$ in all effector:target ratios; Mann-Whitney $U$ test), suggesting that vaccination with S100-β–derived NPPEs activates an ongoing autoimmune response rather than triggering a regulatory one.

**DISCUSSION**

Islet infiltration by both CD4+ and CD8+ T cells is observed in T1D, but several studies have established an important role for the latter. In fact, the cytotoxic effector function of these cells is thought to be one of the mechanisms of β-cell destruction in vivo (38).

During diabetes development, pSC cells, a network of nervous cells surrounding the islet mass, are also targeted by the immune system. In NOD mice, as insulitis progresses, pSC cells are gradually eliminated (16–18). pSC cells express antigens that are either specific, such as GFAP, or shared with the β-cells, such as the neurotrophic factor S100-β (16). Interestingly, many autoantigens targeted by the immune response in T1D are expressed by different nervous and neuroendocrine tissues, such as GAD67, glutamic acid decarboxylase 67, islet cell antigen 512 (also referred to as IA-2), phogrin (also referred to as IA-2–β), islet cell antigen 69, or chromogranin A (39).

Our group was the first to define NPPEs derived from S100-β and restricted by the HLA-DRB1*04:01 (HLA-DR4) class II molecule. T cells from both ND and long-term T1D patients recognized the S100-β–derived NPPEs and secreted IFN-γ (23). In the present study, we defined S10010–18 and S10020–28 as new HLA-A2.1–restricted epitopes. Those epitopes were recognized more frequently by T cells from both ND and long-term T1D patients. Moreover, the frequency of dual responders (i.e., those responding to both S100-β peptides) was higher in T1D patients, particularly long-term ones. Previous studies have shown that different types of autoimmune responses could be taking place in T1D patients. Differential insulitic profiles determine the extent of β-cell destruction and the age at onset (40); therefore, it remains possible that younger T1D patients than the ones shown in our study show more robust S100-β–specific cytotoxic responses, as previously shown by Banwell et al. for whole antigen in children using a proliferation assay (22).
The percentage of islets heavily NPPEs or inoculated with saline. Fisher cinated with S100-b A2.1-transgenic NOD mice vac- Cox, NOD mice. Log-rank, Mantel- development in A2.1-transgenic mice identified dominant class II regions or in close proximity (21, 24, 41). Recent data in NOD mice identified dominant class II-restricted epitopes (S1001-15 and S100 78-97) (25) in regions previously identified by us in human T1D (23). These data point to the fact that those regions are immunodominant in both NOD mice and human T1D patients and constitute important targets of the autoimmune response in diabetes.

Proliferative lymphocyte responses against GFAP and S100-β whole antigens have been detected in both NOD mice and human T1D patients (16, 22). Two GFAP-derived Kd-restricted epitopes have been identified in the NOD mice. However, when evaluated for their potential in preventing diabetes, only the one with the higher MHC binding affinity was able to significantly delay TID development (21). Our results show that responses against HLA-A2.1-restricted S100-β NPPEs can be detected as early as 4 wk of age; however, when used to prevent disease development, an acceleration was observed, more aggressive insulitis was detected, no reduction of IFN-γ secretion was seen, and an increase in cytotoxic activity against S100-β-loaded targets was observed.

Several differences between the present study and those using other peptide antigens to prevent TID could explain the differences. First, GFAP-derived peptide epitopes were identified using algorithms predicting high binders, whereas our S100-β-derived peptide epitopes are true NPPEs with low or no detectable affinity for HLA-A2.1 using an HLA stabilization assay. There is a correlation between class I binding affinity and immunogenicity of CTL peptide epitopes (42). It is believed that peptide epitopes targeted by CTLs administered systemically in high doses and in aqueous solutions induce CTL peripheral tolerance, probably due to the deletion of peptide-specific CTLs (43, 44). For example, a single subcutaneous vaccination using a peptide derived from the adenovirus type 5 early region 1A oncogene induces a specific CTL response in diabetes (44). An important difference between both peptides is their affinity for the restriction element (H-2Db), with a higher binding affinity showing a higher capacity to prevent experimental autoimmune encephalomyelitis and induce tolerance when administered in conditions similar to those shown in the present study (45).

Second, MHC class I-restricted GFAP peptides (21) were administered in incomplete Freund’s adjuvant (IFA) compared with saline in the present study, and this may contribute to their in vivo stability. In cancer animal models, peptide/IFA vaccination primed tumor-specific
CD8+ T lymphocytes. Those cells accumulated and persisted at the antigen-rich vaccination site, where they became dysfunctional and underwent apoptosis, resulting in hyporesponsiveness to subsequent peptide boosts. Vaccination using the same peptides in saline shifted T-cell location toward tumors, inducing anti-tumor activity and reducing systemic T-cell dysfunction (46). These data suggest that antigen clearance promotes CD8+ T-cell survival and generation of memory T cells, whereas chronic antigen stimulation leads to tolerance (47). Performing experiments with S100β-derived NPPEs in IFA will help to test this hypothesis.

Multiple immunizations using an islet-specific glucose-6-phosphatase–related protein–derived peptide in saline protects from diabetes development (30). Repeated triggering of high-avidity CD8+ T cells with a low-avidity, but not with a high-affinity, peptide in the periphery before development of complete insulitis induces tolerance, even when peptides tested show a high affinity for the Kβ MHC molecule. This protection is mediated by the elimination of high-avidity CD8 cells and their substitution by low-affinity peptide-specific cells. There are no data regarding the frequency or avidity of S100β–specific CD8+ T cells in the A2.1-transgenic NOD mice; hence, we speculate that a combination of low affinity for MHC molecules and a quick peptide clearance from the injection site leads to the expansion of high-avidity CD8+ T cells, explaining the acceleration of T1D in vaccinated animals and the simultaneous increase in cytotoxicity against targets preincubated with S100β NPPEs.

Conflicting results regarding a successful outcome (i.e., diabetes prevention) has also been shown for class II–restricted peptide epitopes recognized by CD4+ T lymphocytes. The use of the insulin peptide epitope B9:23 (SHLVEALYLYCGERG) in immunotherapy in the NOD mice has led to 50% protection (48), no effect (49), or an increase in disease incidence (50). To explain these discrepancies, it has been proposed that efficient regulatory T cell induction needs individual peptide optimization and is greatly influenced by the activated status of the target T cells.

Figure 5. T1D diabetes development in A2.1-transgenic NOD mice vaccinated intraperitoneally with low doses of S10010-18 and S10020-28. A) Animals were vaccinated with 10 µg each of S10010-18 and S10020-28 per dose (n = 10; continuous line) starting at 4 wk of age and then every 2–3 wk until they developed diabetes or reached 30 wk of age. Animals inoculated with saline (n = 12; black dotted line) were used as controls. Spontaneous disease development in nonmanipulated females (n = 34; gray dotted line) is also shown. Vaccination with S10010-18 and S10020-28 significantly accelerates the kinetics of diabetes development in A2.1-transgenic mice compared with both saline-treated (log-rank, Mantel-Cox, P = 0.048) and nonmanipulated (log-rank, Mantel-Cox, P = 0.02) female mice. B) Insulitis in A2.1-transgenic NOD mice vaccinated with S100β–derived NPPEs or inoculated with saline. The percentage of islets heavily infiltrated (scores 3 and 4) is significantly higher in S100β–vaccinated animals compared with those inoculated with saline. Fisher’s exact test; P = 0.011. C, D) IFN-γ secretion in response to S10010-18 (C) and S10020-28 (D) in A2.1-transgenic NOD mice vaccinated with the S100β–derived NPPEs (S100β), saline (saline), or nonmanipulated (spontaneous). In all cases, splenocytes were harvested at disease diagnosis or at 30 wk of age. Neither frequency of positive responses (Fisher’s exact test, P > 0.05) nor median SI responses (P = 0.24 for S10010-18 and P = 0.097 for S10020-28; Kruskal-Wallis test) were significantly different in S100β–immunized mice compared with spontaneous and saline-inoculated mice. E) Splenocytes from animals vaccinated with S100β–derived NNPEs (black line) show a higher specific cytotoxicity against targets incubated with both S100β–derived NPPEs compared with that seen in splenocytes from animals inoculated with saline (dotted line). Mann-Whitney U test, P < 0.05 for all effector:target (E:T) ratios.
Finally, although both S100<sub>10-18</sub> and S100<sub>20-28</sub> are NPPEs eluted from HLA-A2.1 molecules, present results show that A2.1-negative T1D patients also respond against these peptide epitopes. These results are not unexpected since previous results have shown a great majority of peptide epitopes elicited responses by individuals not expressing the original restricting HLA molecule, due to promiscuous presentation via two or more HLA class I molecules (51).

In summary, we have identified NPPEs derived from the calcium-binding S100-β antigen and presented by the HLA-A*02:01 molecule. Those CTL peptide epitopes are recognized more frequently by lymphocytes from both ND and long-term T1D patients compared with HDs. Similar responses against these NPPEs can be detected in A2.1-transgenic NOD mice as early as 4 wk of age. Vaccination of A2.1-transgenic NOD mice with these NPPEs seems to accelerate T1D development, increasing insulin and triggering the expansion of S100-β–specific CTLs, probably due to the expansion of high-affinity S100-β–specific cytotoxic T cells, suggesting that the use of short HLA class I–restricted peptides to induce tolerance needs a careful evaluation of the target cytotoxic population to avoid its stimulation.

F

ACKNOWLEDGMENTS

The authors thank Dr. Sefina Arif (King’s College London, London, United Kingdom) for critically reviewing the manuscript. This work was funded by the Ministerio de Economía y Competitividad (Grant BIO2014-53901-C3-3-R to R.V.C.). During this work, I.G.-T. was supported by a Maria Barbeito predoctoral fellowship (Xunta de Galicia, La Coruña, Spain). During this work, C.C.-S. was supported by a Deputación da Coruña grant (Xunta de Galicia, La Coruña, Spain). During this work, I.G.-T. was supported by a Maria Barbeito predoctoral fellowship (Xunta de Galicia, La Coruña, Spain). This work was supported by a Deputación da Coruña grant (2012–2013 and 2016–2017). The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

C. Calviño-Sampedro, I. Gomez-Tourino, O. J. Cordero, and J. E. Viñuela performed research and analyzed data; P. A. Reche, M. Gómez-Perosanz, and J. L. Sánchez-Trincado analyzed the ELISPOT data; A. M. Sueiro identified and selected diabetes patients; M. Á. Rodríguez performed histological analysis; R. V. Calviño designed research and analyzed data; C. Calviño-Sampedro, I. Gomez-Tourino, and R. V. Calviño wrote the manuscript; and all authors revised the manuscript and made intellectual contributions to the work.

REFERENCES

1. Taplin, C. E., and Barker, J. M. (2008) Autoantibodies in type 1 diabetes. Autoimmunity 41, 11–18
2. Coppieters, K. T., Dotta, F., Amirian, N., Campbell, P. D., Kay, T. W., Atkinson, M. A., Roep, B. O., and von Herrath, M. G. (2012) Demonstration of islet-autoimmune CD8 T cells in insulinic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 209, 51–60
3. Roep, B. O., and Peakman, M. (2011) Diabetogenic T lymphocytes in human Type 1 diabetes. Curr. Opin. Immunol. 23, 746–753
4. Anderson, M. S., and Bluestone, J. A. (2005) The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 23, 447–485
5. Liblau, R. S., Wong, F. S., Mars, L. T., and Santamaria, P. (2002) Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention. Immunity 17, 1–6
6. In’t Veld, P., Levens, D., De Gruijs, J., Ling, Z., Van der Auwerda, B., Pipeleers-Marichal, M., Gorus, F., and Pipeleers, D. (2007) Screening for insulitis in adult autoantibody-positive organ donors. Diabetes 56, 2400–2404
7. In’t Veld, P. (2011) Insulitis in human type 1 diabetes: the quest for an elusive lesion. Idés 3, 131–138
8. Wang, B., Gonzalez, A., Benoist, C., and Mathis, D. (1996) The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus. Eur. J. Immunol. 26, 1762–1769
9. Nejentsev, S., Howson, J. M., Walker, N. M., Szeczko, J., Field, S. F., Stevens, H. E., Reynolds, P., Hardy, M., King, E., Masters, J., Hulme, J., Maier, L. M., Smyth, D., Bailey, R., Cooper, J. D., Ribas, G., Campbell, R. D., Clayton, D. G., and Todd, J. A.; Wellcome Trust Case Control Consortium. (2007) Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 450, 887–902
10. Noble, J. A., Valdes, A. M., Varney, M. D., Carlson, J. A., Moonsamy, P., Fear, A. L., Lane, J. A., Lavant, E., Rappner, R., Looney, A., Conccannon, P., Mychaleckyj, J. C., and Erlich, H. A.; Type 1 Diabetes Genetics Consortium. (2010) HLA class I and genetic susceptibility to type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium. Diabetes 59, 2972–2979
11. Willcox, A., Richardson, S. J., Bone, A. J., Foulis, A. K., and Morgan, N. G. (2009) Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 155, 173–181
12. Itoh, N., Hanafusa, T., Miyazaki, A., Miyagawa, J., Yamagata, K., Yamamoto, K., Waguri, M., Imagawa, A., Tamura, S., Inada, M., Kawata S., Tarui S., Kono N., and Matsuzawa Y. (1993) Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J. Clin. Invest. 92, 2313–2322
13. Roep, B. O., and Peakman, M. (2012) Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb. Perspect. Med. 2, a007781
14. Wenzlau, J. M., Juhl, K., Yu, L., Mota, O., Sarkar, S. A., Gottlieb, P., Revers, M., Eisenbarth, G. S., Jensen, J., Davidson, H. W., and Hutton, J. C. (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc. Natl. Acad. Sci. USA 104, 17040–17045
15. Lieberman, S. M., Evans, A. M., Han, B., Takaki, T., Vinniskaya, Y., Caldwell, J. A., Serreze, D. V., Shahabonwiz, J., Hunt, D. F., Nathenson, S. G., Santamaría, P., and Di Lorenzo, T. P. (2003) Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc. Natl. Acad. Sci. USA 100, 8384–8388
16. Winer, S., Tsui, H., Lau, A., Song, A., Li, X., Cheung, R. K., Sampson, A., Aifiani, F., Elford, A., Jackson, C., Becker, D. J., Santamaría, P., Ohashi, P., and Dosch, H. M. (2003) Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat. Med. 9, 198–205
17. Teng, S. C., Chiu, Y. C., Hu, C. T., Peng, S. J., and Fu, Y. Y. (2013) Plasticity of Schwann cells and pericytes in response to islet injury in mice. Diabetologia 56, 2424–2434
18. Wener, H., Schwab, M., Linnington, C., and Meyermann, R. (1986) Antigen presentation in the peripheral nervous system: Schwann cells present endogenous myelin autoantigens to lymphocytes. Eur. J. Immunol. 16, 1551–1557
19. Gómez-Acebes, I., Camarín-Daiña, F., Otero-Romero, I., Rodríguez, M. A., Hernández-Fernández, A., González-Fernández, A., Pena-González, E., Rodríguez, J., Rodríguez-Segade, S., and Varela-Calvino, R. (2010) Autoantibodies to giall fibbrillary acid protein and S100beta in diabetic patients. Diabet. Med. 27, 246–248
20. Barbulo, P. D., Lebovitz, E. E., Bren, K. E., Bayat, A., Paviol, S., Wenzlau, J. M., Barriga, K. J., Revers, M., Harlan, D. M., and Iadarola, M. J. (2012) Extrapancratic autoantibody profiles in type 1 diabetes. PLoS One 7, e45216
21. Tsui, H., Chan, Y., Tang, L., Winer, S., Cheung, R. K., Palser, G., Selvanantham, T., Elford, A. R., Ellis, J. R., Becker, D. J., Ohashi, P. S., and Dosch, H. M. (2008) Targeting of pancreatic glia in type 1 diabetes. Diabetes 57, 918–928
22. Banwell, B., Bar-Or, A., Cheung, R., Kennedy, J., Krupp, L. B., Becker, D. J., and Dosch, H. M.; Walsworth Pediatric Multiple Sclerosis Study Group. (2008) Abnormal T-cell reactivities in childhood
inflammatory demyelinating disease and type 1 diabetes. *Ann. Neurol.* 63, 98–111.

23. Gómez-Toumín, I., Simón-Vázquez, R., Alonso-Lorenzo, J., Arif, S., Calviño-Sampedro, C., González-Fernández, A., Pena-González, E., Rodríguez, J., Vitiuela-Roldán, J., Verdaguer, J., Cordero, O. J., Peakman, M., and Varela-Calvino, R. (2015) Characterization of the autoimmune response against the nerve tissue S100B in patients with type 1 diabetes. *Clin. Exp. Immunol.* 180, 207–217.

24. Standifer, N. E., Ouyang, Q., Panagiotopoulos, C., Verchere, C. B., Tan, R., Greenbaum, C. J., Phoker, C., and Nepom, G. T. (2006) Identification of Novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives. *Diabetes* 55, 3061–3067.

25. Serre, L., Fazilleau, N., and Guerder, S. (2015) Central tolerance spares the private high-affinity CD4(+) T-cell repertoire specific for an islet antigen in NOD mice. *Eur. J. Immunol.* 45, 1946–1956.

26. Diez-Rivero, C. M., Lafuente, E. M., and Reche, P. A. (2010) Computational analysis and modeling of cleavage by the immunoproteasome and the constitutive proteasome. *BMC Bioinformatics* 11, 479.

27. Nussbaum, A. K., Kuttler, C., Hadeler, K. P., Rammensee, H. G., and Schild, H. (2001) PaProC: a prediction algorithm for proteasomal cleavages available on the WWW. *Immunogenetics* 53, 87–94.

28. Varela-Calvino, R., Skowera, A., Arif, S., and Peakman, M. (2004) Identification of a naturally processed cytosolic CD8 T-cell epitope of coxsackievirus B4, presented by HLA-A2.1 and located in the PEV-KEK region of the P2C nonstructural protein.

29. Edelstein-Keshet, L., and Santamaria, P. (2005) Prevention of therapy precipitates type 1 diabetes.

30. Leete, P., Wilcock, A., Krogvold, L., Dahl-Jørgensen, K., Foulis, A. K., Richardson, S. J., and Morgan, N. G. (2016) Differential insulitic profiles determine the extent of β-cell destruction and the age at onset of type 1 diabetes. *Diabetes* 65, 1362–1369.

31. Neri, S., Mariani, E., Meneghetti, A., Cattini, L., and Facchini, A. (2011) HLA class I allele promiscuity revisited.

32. Daniel, C., Weigmann, B., Bronson, R., and von Boehmer, H. (2011) CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated proproinsulin epitope. *J. Clin. Invest.* 118, 3390–3402; erratum: 119, 2844.

33. Skowera, A., Ellis, R. J., Varela-Calvino, R., Arif, S., Huang, G. C., Van-Krüns, C., Zaremba, A., Rackham, C., Allen, J. S., Tree, T. I., Zhao, M., Dayan, C. M., Sewell, A. K., Unger, W. W., Drifhout, J. W., Osendorf, F., Roep, B. O., and Peakman, M. (2008) CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated proproinsulin epitope. *J. Clin. Invest.* 118, 3390–3402; erratum: 119, 2844.

34. Varela-Calvino, R., Khadra, A., and Pietropaolo, M. (2015) Immunogenetics of type 1 diabetes mellitus. *Mol. Aspects Med.* 42, 46–60.

35. Andreatta, M., and Nielsen, M. (2012) Immune epitope database analysis ranking potential HLA-A2 binding peptides based on independent epitopes.

36. Kim, Y., Ponomarenko, J., Zhu, Z., Tamang, D., Wang, P., Reche, P. A., Glutting, J. P., Zhang, H., and Reinherz, E. L. (2004) Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. *Proc. Natl. Acad. Sci. U.S.A.* 91, 444–448.

37. Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J., and Kast, W. M. (1996) Peptide vaccination can lead to enhanced tumour growth through specific T-cell tolerance induction. *Proc. Natl. Acad. Sci. U.S.A.* 93, 7855–7860.

38. Liu, G. Y., and Wraith, D. C. (1995) Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult mice—implications for autoimmunity.

39. Hailemichael, Y., Dai, Z., Jaffarzad, N., Ye, Y., Medina, M. A., Huang, X. F., Dotta-Estremera, S. M., Greci, N. R., Nitti, G., Peng, W., Liu, C., Lou, Y., Wang, Z., Ma, W., Rabinovich, B., Sowell, R. T., Schluns, K. S., Davis, R. E., Hwu, P., and Overwijk, W. W. (2013) Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. *Nat. Med.* 19, 345–347.

40. Redmond, W. L., and Sherman, L. A. (2005) Peripheral tolerance of CD8 T lymphocytes. *Immunol. Rev.* 227, 275–284.

41. Liu, E., Abiru, N., Moriyama, H., Miao, D., and Eisenbarth, G. S. (2002) Induction of insulin autoantibodies and protection from diabetes with subcutaneous insulin B9-23 peptide without adjuvant. *Ann. N. Y. Acad. Sci.* 958, 224–227.

42. Daniel, C., Weigmann, B., Bronson, R., and von Boehmer, H. (2011) Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. *J. Exp. Med.* 208, 1501–1510.

43. Bergman, M. L., Lopes-Carvalho, T., Martins, A. C., Grieco, F. A., Eizirik, D. L., and Demengeot, J. (2017) Tolerogenic insulin peptide therapy precipitates type 1 diabetes. *J. Exp. Med.* 214, 2153–2166.

44. Rao, X., Hoof, I., Fontaine Costa, A.I.C.A., van Baarle, D., and Kesmir, C. (2011) HLA class I allele promiscuity revisited. *Immunogenetics* 63, 691–701.

Received for publication October 23, 2018. Accepted for publication January 22, 2019.